Oxycellulose as mucoadhesive polymer in buccal tablets

Drug Development and Industrial Pharmacy

Volumn 36, Issue 9, 2010, Pages 1115-1130

  Jan, Gajdziok ^a   Martina, Bajerov ^a   Zuzana, Chalupov ^a   Miloslava, Rabikov ^a  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

Buccal mucoadhesive tablets; Cetylpyridinium chloride; In vitro tablet characterization; Oxycellulose sodium; Prolonged drug release

Indexed keywords

CETYLPYRIDINIUM SALT; HYDROXYPROPYLMETHYLCELLULOSE; OXIDIZED CELLULOSE; POLYMER;

AQUEOUS SOLUTION; ARTICLE; DRUG RELEASE; MEAN RESIDENCE TIME; MUCOADHESION; PHYSICAL CHEMISTRY; SOLUBILITY; TABLET; TABLET FRIABILITY; TABLET HARDNESS; TABLET THICKNESS; TENSILE STRENGTH;

ADHESIVENESS; ADMINISTRATION, BUCCAL; ANTI-INFECTIVE AGENTS, LOCAL; CETYLPYRIDINIUM; CHEEK; DRUG CARRIERS; EXCIPIENTS; METHYLCELLULOSE; MOUTH MUCOSA; PARTICLE SIZE; POLYMERS; SOLUBILITY; TABLETS; VISCOSITY;

EID: 77956400602     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639041003690031     Document Type: Article

References (51)

1. Witt J, Ramji N, Gibb R, Dunavent J, Flood J, Barnes J. (2005). Antibacterial and antiplague effects of a novel, alcohol-free oral rinse with cetylpyridinium chloride. J Contemp Pract, 6:1-10.
2. Roberts WR, Addy M. (1981). Comparison of the in vivo and in vitro antibacterial properties of antiseptic mouthrinses containing chlorhexidine, alexidine, cetyl pyridinium chloride and hexetidine. Relevance to mode of action. J Clin Periodontol, 8, 295-310. (Pubitemid 11008406)
3. Addy M. (1994). Local delivery of antimicrobial agents to the oral cavity. Adv Drug Deliv Rev, 13:123-34.
4. Busscher HJ, White DJ, Atema-Smit J, Geertsema-Doornbusch G, de Vries J, and van der Mei HC. (2008). Surfactive and antibacterial activity of cetylpyridinium chloride formulations in vitro and in vivo. J Clin Periodontol, 35:547-54.
5. Ali J, Khar R, Ahuja A, Kalra R. (2002). Buccoadhesive erodible disk for treatment of oro-dental infections: design and characterisation. Int J Pharm, 283:93-103.
6. Nafee NA, Boraie NA, Ismail FA, Mortada LM. (2003). Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm, 53:199-212.
7. Kuna M, Rabišková M. (2007). Mucoadhesive tablets for oral administration of ciclopiroxolamine. Ceska Slov Farm, 56:243-8.
8. Nafee NA, Boraie NA, Ismail FA, Mortada LM. (2004). Mucoadhesive delivery systems. I. Evaluation of mucoadhesive polymers for buccal tablet formulation. Drug Dev Ind Pharm, 30:985-93.
9. Gandhi RB, Robinson JR. (1994). Oral cavity as a site for bioadhesive drug delivery. Adv Drug Deliv Rev, 13:43-74.
10. Bruschi ML, de Freitas O. (2005). Oral bioadhesive drug delivery systems. Drug Dev Ind Pharm, 31:293-310.
11. Lee WJ, Park JH, Robinson JR. (2000). Bioadhesive-based dosage forms: The next generation. J Pharm Sci, 89:850-66.
12. Serra L, Doménech J, Peppas NA. (2009). Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. Eur J Pharm Biopharm, 71:519-28.
13. Jinsong Hao KC, Heng PWS. (2003). Buccal delivery systems. Drug Dev Ind Pharm, 29:821-33.
14. Salamat-Miller N, Chittchang M, Johnston TP. (2005). The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev, 57:1666-91.
15. Ceschel GC, Bergamante V, Calabrese V, Biserni S, Ronchi C, Fini A. (2006). Design and evaluation in vitro of controlled release mucoadhesive tablets containing chlorhexidine. Drug Dev Ind Pharm, 32:53-61.
16. Hagesaether E, Sande SA. (2007). In vitro measurements of mucoadhesive properties of six types of pectin. Drug Dev Ind Pharm, 33:417-25.
17. Onishi H, Machida Y, Koyama K. (2007). Preparation and in vitro characteristics of lactoferrin-loaded chitosan microparticles. Drug Dev Ind Pharm, 33:641-7.
18. Surapaneni M, Das S, and Das N. (2006). Effect of excipient and processing variables on adhesive properties and release profile of pentoxifylline from mucoadhesive tablets. Drug Dev Ind Pharm, 32:377-87.
19. Dvoráková K. (2009). Drug release from oral matrix tablets containing hypromellose. Chem Listy, 103:66-72.
20. Schmidt R, Bogan D, Moore J. (2001). Use of oxidized cellulose as free radical scavenger. EU Patent Office, Pat No 1153618.
21. Watt PW, Harvey W, Wiseman D, Light N, Saferstein L, Cini J. (2003). Use of oxidized cellulose and complexes thereof for chronic wound healing. EU Patent Office, Patent No 0918548.
22. Zimnitsky DS, Yurkshtovich TL, Bychkovsky PM. (2004). Synthesis and characterization of oxidized cellulose. J Polym Sci A Polym Chem, 42:4785-91.
23. Delattre C, Michaud P, Elboutachfaiti R, Courtois B, Courtois J. (2006). Production of oligocellouronates by biodegradation of oxidized cellulose. Cellulose, 13:63-71.
24. Watt PW, Harvey W, Lorimer E, Wiseman D. (1998). Use of oxidized cellulose and complexes thereof for chronic wound healing. World Patent Office, Patent No 9800180.
25. Saferstein L, Wolf S, Kamp L, Linsky C, Wiseman D. (1991). Process for preparing a neutralized oxidized cellulose product and its method of use. EU Patent Office, Patent No EP0437095.
26. Sheleg SV, Korotkevich EA, Zhavrid EA, Muravskaya GV, Smeyanovich AF, Shanko YG, et al. (2002). Local chemotherapy with cisplatin- depot for glioblastoma multiforme. J Neurooncol., 60, 53-9.
27. Cohen EC. (1986). Microencapsulated astringent hemostatic agents and methods of use. US Patent Office, Patent No 4,597,960.
28. Zhu L, Kumar V, Banker GS. (2000). Examination of oxidized cellulose as a macromolecular prodrug carrier: Preparation and characterization of an oxidized cellulose-phenylpropanolamine conjugate. Int J Pharm, 223, 35-47.
29. Zhu L, Kumar V, Banker GS. (2004). Examination of aqueous oxidized cellulose dispersions as a potential drug carrier: II. In vitro and in vivo evaluation of phenylpropanolamine release from microparticles and pellets. AAPS PharmSciTech, 5(4): article 70.
30. Zimnitsky DS, Yurkshtovich TL, Bychkovsky PM. (2005). Multilayer adsorption of amino acids on oxidized cellulose. J Colloid Interface Sci, 285:502-8.
31. Bala K, Guha SK, and Vasudevan P. (1982). p-Amino salicylic acid-oxidized cellulose system: A novel for long term drug delivery. Biomaterials, 3:113-21.
32. Gert EV, Torgashov VI, Zubets OV, Kaputskii FN. (2005). Preparation and properties of enterosorbents based on carboxylated microcrystalline cellulose. Cellulose, 12:517-26.
33. Gert EV, Torgashov VI, Zubets OV, Kapustkii FN. (2006). Combination of oxidative and hydrolytic functions of nitric acid in productions of enterosorbents based on carboxylated microcrystalline cellulose. Russ J Appl Chem Eng Tr, 79:1896-901.
34. Bajerová M, Gajdziok J, Dvorá2ková K, Masteiková R, and Kollár P. (2008). Polosyntetické deriváty celulosy jako základ hydrofilních gelových systému. Ceska Slov Farm, 57:63-9.
35. Takahashi Y, Takeda C, Seto I, Kawano G, Machida Y. (2007). Formulation and evaluation of lactoferrin bioadhesive tablets. Int J Pharm, 343:220-7.
36. Khanna R, Agarwal SP, Ahuja A. (1996). Preparation and evaluation of bioerodible buccal tablets containing clotrimazole. Int J Pharm, 138:67-73.
37. Munasur AP, Pillay V, Chetty DJ, Govender T. (2006). Statistical optimisation of the mucoadhesivity and characterisation of multipolymeric propranolol matrices for buccal therapy. Int J Pharm, 323:43-51.
38. Duchene D, Ponchel G. (1997). Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm, 44:15-23.
39. Smart JD. (1993). Drug delivery using buccal-adhesive systems. Adv Drug Deliv Rev, 11:253-70.
40. El-Samaligy MS, Yahia SA, Basalious EH. (2004). Formulation and evaluation of diclofenac sodium buccoadhesive discs. Int J Pharm, 286:27-39.
41. Bettini R, Colombo P, Massimo G, Catellani PL, and Vitali T. (1994). Swelling and drug release in hydrogel matrices: polymer viscosity and matrix porosity effects. Eur J Pharm Sci, 2:213-9.
42. Conti S, Maggi L, Segale L, Ochoa Machiste E, Conte U, Grenier P, et al. (2007). Matrices containing NaCMC and HPMC: 1. Dissolution performance characterization. Int J Pharm, 333:136-42.
43. Rabišková M, Chalabala M, Chalupová Z, Masteiková R, Vitková M, Gleich S. (2006). Dosage forms as aplication systems. In: Komárek P,Rabišková M, eds. Pharmaceutics. Praha: Galén, 204-248.
44. Karavas E, Georgarakis E, Bikiaris D. (2006). Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics. Eur J Pharm Biopharm, 64:115-26.
45. Tobyn MJ, Johnson JR, Dettmar PW. (1996). Factors affecting in vitro gastric mucoadhesion: II. Physical properties of polymers. Eur J Pharm Biopharm, 42:56-61.
46. Juarez H, Rico G, Villafuerte L. (2001). Influence of admixed carboxymethylcellulose on release of 4-aminopyridine from hydroxypropyl methylcellulose matrix tablets. Int J Pharm, 216:115-25.
47. Dow Chemical Company. (2009). Mucoasal biodhesives, company materials. http://www.dow.com [accessed February 18, 2010].
48. Colorcon Limited.(2008). Using METHOCEL cellulose ethers for controlled release of drugs in hydrophilic matrix systems, company materials. http://www.colorcon.com [accessed February 18 2010]
49. Sovilj V, Petrovic L. (2007). Interaction and phase separation in the system HPMC/NaCMC/SDS. Colloid Surf A, 298:94-8.
50. Conti S, Maggi L, Segale L, Ochoa Machiste E, Conte U, Grenier P, et al. (2007). Matrices containing NaCMC and HPMC: 2. Swelling and release mechanism study. Int J Pharm, 333:143-51.
51. Vetchý D, Vetchá M, Rabišková M, Gryczová E, Bartošíková L. (2007). Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug. Medicina, 43:326-31.